Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' Reply

Astrid Lièvre (1, 2) , Jean-Louis Merlin (3, 4) , Jean-Christophe Sabourin (5, 6) , Pascal Artru (7) , Pierre Laurent-Puig (8) , Michel Ducreux (9)

1 CHU Pontchaillou [Rennes]
2 COSS - Chemistry, Oncogenesis, Stress and Signaling
3 CRAN - Centre de Recherche en Automatique de Nancy
4 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
5 CHU Rouen
6 GMFC - Génétique du cancer et des maladies neuropsychiatriques
7 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
8 ICPH - Intéractions cellulaires et physiopathologie hépathique (Orsay, Essonne) UMRS 1174
9 Département de médecine oncologique [Gustave Roussy]

We thank Dr. Barel et al. for their letter concerning our article [1]. In this letter, the authors reported their experience of 1264 RAS tests performed between 2015 and 2017 in a French area of Brittany using a massively parallel sequencing method. Even if the mean duration between receipt of tumour samples by the molecular genetics platform and the transmission of the RAS test report was shorter than that we previously reported (11.03 days versus 19.5 in our study), it exceeds anyway the recommended duration between test request and results feedback [2–4].

Keywords: turnaround time; RAS mutation; colorectal cancer; quality

Domains: Life Sciences [q-bio]; Cancer; Life Sciences [q-bio]; Human health and pathology; Hépatology and Gastroenterology; Life Sciences [q-bio]; Genetics; Human genetics

Astrid Lièvre, Jean-Louis Merlin, Jean-Christophe Sabourin, Pascal Artru, Pierre Laurent-Puig, et al.. Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' Reply. Digestive and Liver Disease, 2018, 50 (9), pp.974-975. ⟨10.1016/j.dld.2018.06.014⟩. ⟨hal-01902490⟩